Pfizer has discontinued development of a PD-L1–targeting therapy that had been under early-stage investigation across multiple cancer types.
The phase...
Executive Summary
Sustainable practices in pharmaceutical manufacturing in 2026 are transitioning from compliance-driven initiatives to core operational strategy. The direct...
Executive Summary
Macroeconomic conditions are significantly reshaping pharma and biotech funding in 2026, shifting the industry from capital abundance to...